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Purpose: To compare different techniques of transfection of primary human corneal endothelial cells (HCECs) by non-
viral methods and to enrich genetically modified cells to a highly pure population.
Methods: HCECs were cultured following previously published methods. Dissection of the Descemet membrane (DM)
was performed by tearing off strips from corneal buttons with forceps or by hydrodissection. Confirmation of HCECs
identity  was  performed  by  reverse  transcriptase  polymerase  chain  reaction  (RT–PCR)  for  α2  collagen  VIII.  For
transfection,   non-viral   methods   such   as   lipid-/liposome-mediated   reagents   and  electroporation  techniques  were
compared. Genetically modified cells were enriched by use of selection antibiotics and flow cytometry.
Results:  Viability  of  primary  HCECs  was  lower  in  hydrodissected  corneas.  The  rate  of  transfection  varied  from
approximately 5%–30%. Highest rates of transfection were obtained with the Amaxa electroporation method. The next
highest rate was yielded by the lipid-mediated reagent GenCarrier2, followed by electroporation with the BTX apparatus.
Toxicity was moderate and manageable by adjusting the concentration of reagents, incubation times, and electrical
parameters. Selection by flow cytometry was superior to antibiotic selection and produced nearly 100% genetically
modified cells.
Conclusions: Electroporation of HCECs yields higher transfection efficiency than chemically mediated methods. It is
possible to select genetically modified HCECs to high levels of homogeneity. Techniques to genetically modify and select
HCECs as shown in this study could lead to improved success of future endothelial transplant procedures.
Corneal  endothelial  failure  is  a  major  indication  for
corneal transplantation. A leading cause of endothelial failure
is  Fuchs  endothelial  dystrophy  (FED).  This  disease  is
characterized by a slow, continuous loss of morphologically
and  physiologically  altered  endothelial  cells,  eventually
leading  to  corneal  edema  and  a  thickened  Descemet
membrane (DM) with focal excrescences of altered basement
membrane  material  (guttae)  [1,2].  Collagen  VIII,  which
includes α1 and α2 chains, is produced by corneal endothelial
cells and is an important structural component of DM. At least
two  different  mutations  in  the  α2  chain  of  collagen  VIII
(COL8A2) have been shown to cause early-onset FED [3,4].
Finding a way to use modified human corneal endothelial cells
(HCECs) as an approach for cellular or gene therapy and to
avoid  the  need  for  corneal  transplantation  would  be  a
promising goal. The objective would be to either restore the
physiologic  functions  of  diseased  endothelial  cells  or  to
successfully transplant healthy endothelial cells alone.
Potential  therapeutic  uses  of  cultured  HCECs  may
improve from the ability to genetically modify these cells in
a safe and reliable manner. To date, the highest rates of genetic
modification of HCECs have been reported for viral vectors,
and less promising results have been reported for genetic
modification of HCECs by non-viral methods. The use of viral
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vectors bears potential risks such as malignant transformation
and immune responses to viral proteins [5]. In addition, the
ability to select genetically modified HCECs to a high level
of homogeneity may yield advantages if such cells were to be
used for a therapeutic application. In this study, we directly
compared non-viral methods of transfection such as lipid-/
liposome-mediated reagents and electroporation techniques
for transfection efficiency and toxicity in HCECs. We also
investigated  antibiotic  selection  and  flow  cytometry  as
methods  to  enrich  populations  of  genetically  modified
HCECs.
METHODS
Research  methods  described  adhered  to  the  tenets  of  the
Declaration of Helsinki.
Serum-free  medium  (OptiMEM-I,  Dulbecco),
phosphate-buffered saline (PBS), and gentamicin and trypsin-
ethylene diamine tetraacetic acid (EDTA) were obtained from
Gibco  BRL/Life  Technologies  (Rockville,  MD).  Mouse
submaxillary gland nerve growth factor and bovine pituitary
extract  were  obtained  from  Biomedical  Technologies
(Stoughton, MA), and mouse submaxillary gland epidermal
growth factor was obtained from Upstate Biotechnologies
(Lake Placid, NY). Fetal bovine serum (FBS) was obtained
from Hyclone (Logan, UT), and ascorbic acid, chondroitin
sulfate,  calcium  chloride,  0.02%  EDTA  solution,
dimethylsulfoxide (DMSO), antibiotic antimycotic solution,
agarose,  ethidium  bromide,  and  0.4%  trypan  blue  were
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629obtained  from  Sigma  (St.  Louis,  MO).  The  following
materials were obtained from companies noted in parentheses:
cell  attachment  reagent  (FNC  coating  mix;  Athena
Environmental  Sciences  Inc.,  Baltimore,  MD),  Fugene
(Roche  Diagnostics,  Basel,  Switzerland),  lipofectin,  Plus
Reagent, TAE buffer, DNase I Amplification Grade (all from
Invitrogen,  Carlsbad,  CA),  GenCarrier2  (Epoch  Biolabs,
Missouri City, TX), plasmids pIRES-EGFP and pEGFP-N1
(BD Biosciences Clontech, Mountain View, CA), and Amaxa
Reagent  Solution  Kit  for  mammalian  endothelial  cells,
pmaxGFP (Amaxa Inc., Gaithersburg, MD).
Human corneal endothelial cell culture: Corneas from
donors aged 27−73 years stored in corneal preservation media
(Optisol-GS; Bausch & Lomb, Rochester, NY) were obtained
from Tissue Banks International (Baltimore, MD).
Human endothelial cell lines were established according
to  previously  published  protocols  [6,7].  Corneas  were
removed from corneal preservation media and were washed
with culture medium consisting of Opti-MEM I, 8% FBS, 5
ng/ml epidermal growth factor (EGF), 20 ng/ml nerve growth
factor (NGF), 100 µg/ml pituitary extract, 20 µg/ml ascorbic
acid, 200 mg/l calcium chloride, 0.08% chondroitin sulfate,
50  µg/ml  gentamicin,  and  antibiotic  antimycotic  solution
diluted 1/100.
Two  methods  were  used  to  remove  DM  with  intact
endothelium.  In  the  first  method,  strips  of  DM  and
endothelium were dissected from corneal buttons. In a second
method, sterile saline was carefully injected in the posterior
stroma with a fine needle. This leads to the formation of a bleb
under DM. After expansion of this bleb almost to the limbus,
the  saline  was  carefully  removed.  DM  together  with
endothelial  cells  was  incised  with  a  trephine  blade  and
removed from the underlying stroma.
The  harvested  DM/endothelial  tissues  were  then
incubated in culture medium overnight at 37 °C under 5%
CO2  and  were  then  centrifuged  at  504x  g  for  6  min  and
incubated in 0.02% EDTA for 1 h at 37 °C to loosen cell-cell
junctions. The tissue was then manually disrupted by passage
through a flame-polished glass pipette. The dissociated cells
were centrifuged again at 504x g for 6 min, and the pellet was
gently resuspended in culture medium.
In another method, the DM and endothelial cell strips
were incubated for 30–60 min in trypsin-EDTA to enhance
the loosening of the cell-cell junctions before passage through
a flame-polished pipette.
Isolated cells and pieces of DM were plated in a single
well  of  a  six-well  tissue  culture  plate  pre-coated  with  an
undiluted cell attachment reagent. Cultures were incubated at
37 °C in a 5% CO2 humidified incubator, and the medium was
changed  every  other  day.  Once  the  cells  approached
approximately 80%–90% confluence, the cells were treated
with  trypsin-EDTA  and  passaged  at  suitable  ratios.
Cryopreservation was performed as described previously [8].
Cell  lines  used  for  transfection  experiments  had  been
passaged between four and six times, and some cell lines had
been used thawed after cryopreservation.
Human  corneal  stromal  fibroblast  culture:  Stromal
fibroblast  cultures  were  established  as  follows.  The
epithelium and endothelium were removed from the corneal
buttons. The corneal button was left in culture medium (same
as that used for growing endothelial cells) for one to two
weeks  until  a  monolayer  of  spindle-shaped  cells  (stromal
fibroblasts) was established along the bottom of the tissue
culture  plate.  The  medium  was  changed,  and  cells  were
passaged at appropriate time intervals.
Reverse transcriptase polymerase chain reaction: Total
RNA was prepared for reverse transcriptase polymerase chain
reaction (RT–PCR) from cultured HCECs, which were 70–
80%  confluent  at  the  time  of  harvest.  A  commercially
available kit was used (RNeasy Mini Kit; Qiagen, Valencia,
CA).
RT–PCR for COL8A2 was performed on a thermal cycler
(DNA engine; Bio-Rad, Hercules, CA). Primers for COL8A2
spanned one intron to distinguish amplification of genomic
DNA. Primer sequences were as follows: sense primer: 5′-
ATC CAG CCC ATG CAG AAA G-3′, antisense primer: 5′-
GCT CTC CCT TCA GGT CCA T-3′. The expected product
length  was  106  base  pairs.  For  β-actin,  a  commercially
available primer set was used (Stratagene, La Jolla, CA).
Sequence of the sense primer was 5′-TGA CGG GGT CAC
CCA CAC TGT GCC CAT CTA-3′. The antisense primer
sequence was 5′-CTA GAA GCA TTT GCG GTG GAC GAT
GGA GGG-3′. As a negative control, total RNA of human
mononuclear cells (StemCell Technologies Inc., Vancouver,
Canada) was used.
RT–PCR  was  performed  for  25  cycles  using
commercially available reagents and protocols (SuperScript
One-Step  RT-PCR  System  with  Platinum  Taq  DNA
Polymerase; Invitrogen). RT–PCR steps were as follows: 1
cycle of 30 min at 55 °C and 2 min at 94 °C followed by 25
cycles of 15 s at 95 °C, 1 min at 50 °C, 1 min at 72 °C, and 1
cycle of 5 min at 72 °C. DNase treatment of RNA samples
was  performed  to  rule  out  genomic  DNA  contamination
following  manufacturer’s  protocols  (Roche  Applied
Diagnostics,  Mannheim,  Germany).  Samples  were
electrophoresed  in  2%  agarose  gels  containing  ethidium
bromide and photographed using standard methods.
Transfection of human endothelial cells:
Lipid-/Liposome-mediated methods—   
For transfection, the following commercially available lipid-/
liposome-mediated  reagents  were  used  and  optimized
according  to  manufacturer’s  protocols:  Fugene,  lipofectin,
Plus Reagent, and GenCarrier2. Transfection procedures were
performed on attached cells with Fugene and lipofectin. With
Fugene,  various  ratios  of  reagent  (µl):DNA  (µg)  were
compared  (3:1,  3:2,  6:1,  9:1,  and  12:1).  With  lipofectin,
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25:2. PlusReagent was added according to manufacturer’s
recommendations in some experiments for enhancement of
transfection efficiency. Incubation time was 18 h or 24 h. With
GenCarrier2, transfection was performed on cell suspensions.
Ratio of reagent:DNA was 18:3, and incubation time was 45
min. Confluence of cells on the day of transfection was 50%–
70%.  The  cell  line  used  was  from  a  38-year-old  donor,
harvested by forceps stripping. Cells had been thawed after
cryopreservation. Each condition was performed at least three
times.
We used plasmids, pIRES-EGFP and pEGFP-N1, both of
which contain an enhanced green fluorescent protein (EGFP)
marker  gene  as  well  as  a  kanamycin/neomycin  resistance
gene. The plasmid, pmaxGFP, without a neomycin resistance
gene was used with the Amaxa method (see next paragraph).
Transfection  procedures  were  optimized  using
manufacturer’s  protocols.  The  rate  of  transfection  was
monitored  by  fluorescence  microscopy.  In  some  cases,  a
selection antibiotic (neomycin) was added (200–300 µg/ml)
48 h after transfection.
Electroporation—           Two different electroporation
methods were compared, BTX (BTX electroporator ECM
830,  BTX  Instrument  Division;  Harvard  Apparatus,
Holliston, MA) and the Amaxa Nucleofector II (Amaxa).
BTX  electroporation  was  performed  with  various  electric
parameters. The first setting consisted of three pulses, pulse
length 1 ms, interval 100 ms. Voltage ranged from 50 to 200
TABLE 1. DONOR INFORMATION OF ALL CORNEAS USED FOR CULTURE OF HCECS.
Donor number Age (years) Days in Storage Method Success
1 53 5 hydrodissection no
2 53 5 hydrodissection no
3 62 9 hydrodissection no
4 72 7 hydrodissection no
5 64 8 hydrodissection no
6 64 5 hydrodissection no
7 55 15 hydrodissection no
8 55 15 hydrodissection no
9 62 12 hydrodissection no
10 66 7 hydrodissection yes
11 55 7 hydrodissection yes
12 63 6 hydrodissection yes
13 17 14 hydrodissection no
14 24 4 hydrodissection no
Mean±SD 55±16 9±4
15 38 7 forceps no
16 38 7 forceps yes
17 65 6 forceps no
18 65 6 forceps no
19 49 5 forceps no
20 49 5 forceps no
21 54 13 forceps no
22 54 13 forceps no
23 62 9 forceps no
24 72 7 forceps no
25 60 19 forceps no
26 73 3 forceps no
27 73 3 forceps yes
28 46 10 forceps no
29 62 12 forceps no
30 66 7 forceps yes
31 27 19 forceps yes
32 27 19 forceps yes
33 63 6 forceps yes
34 17 14 forceps no
35 24 4 forceps yes
Mean±SD 52±17 9±5
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631V. In a second setting we applied one pulse, pulse length 70
ms. Voltage applied also ranged from 50 to 200 V. In all
experiments, a cuvette with a 2 mm gap was used. Cell line
used  was  the  same  as  the  one  used  with  lipid-/liposome-
mediated methods (38-year-old donor, harvested by forceps
stripping, cells had been thawed after cryopreservation). Each
setting was performed once.
With the Amaxa electroporation method, we used the
specific reagents and programs recommended for mammalian
endothelial  cells  (programs  M-03,  T-05,  T-23,  T-27,  and
U-11). All five programs were tested once. In the following
four replicates, only programs T-23 and T-27 were used. Cell
lines used were from donors aged 24, 38 (in two out of five
experiments), 27, and 66 years. All cell lines were harvested
by  forceps  stripping  except  for  one  case  and  had  been
cryopreserved before use.
Selection  by   antibiotics/flow  cytometry  with  fluores-
cence-activated  cell  sorting:             In  experiments  with
neomycin, the minimum dose required to kill primary, non-
transformed  cells  had  been  determined  previously  to  be
300 µg/ml. Neomycin was added to the growth medium 48 h
after transfection. In all cases, neomycin was removed from
the medium after 10 days. Flow cytometry with fluorescence-
activated cell sorting (FACS, MoFlo High-Performance Cell
Sorter; Cytomation, Fort Collins, CO) for EGFP expression
was performed to select fluorescent cells into a highly pure
population.
Light and fluorescence microscopy: Cells were viewed
and  photographed  with  an  inverted  light  and  fluorescent
digital microscopy/photography system (Axiovert 2000 M;
Carl Zeiss Microimaging, Thornwood, NY).
Figure 1. Comparison of success of harvesting methods. Forceps
stripping yielded successful cell lines in 33.3%, and hydrodissection
in 21.4% of all corneas used with these methods, respectively. The
asterisk indicates p≤0.05 (χ2-test)
Statistical analysis: Determination of transfection rate
was  performed  by  counting  EGFP-positive  cells  using
fluorescence microscopy. Statistical analysis was performed
with Microsoft Office Excel 2003 (Microsoft, Redmond, WA)
and GraphPad Prism 4 (GraphPad, La Jolla, CA). p values
were calculated using an unpaired t-test or χ2 test. p values less
than or equal to 0.05 were considered statistically significant.
RESULTS
Culturing  of  human  corneal  endothelial  cells:  Thirty-five
corneas were obtained to attempt culturing of HCECs (Table
1). The donor age was 53±16 (mean±SD) years. Cell lines
were established successfully for 10 (29%) of the corneas.
Age (mean±SD) of the donors yielding cell lines was 50±19
years, and age of donors with failed cultures was 54±15 years
(p>0.05). Days in storage of successful corneas were 9±6.
Days  in  storage  of  failed  corneas  were  9±4  (p>0.05).
Endothelial cells of older donors tended to grow more slowly
and often stopped growing after one to two weeks without
reaching confluence. These cells were more often irregularly
formed and more often exhibited a fibroblastic phenotype as
reported previously [9]. Hydrodissection was performed in 14
corneas. Hydrodissected corneas resulted in fewer viable cell
lines  compared  to  the  ones  stripped  with  forceps.
Hydrodissection  yielded  viable  cell  lines  for  3  out  of  14
(21.4%) corneas whereas forceps stripping was successful for
7 out of 21 (33.3%) corneas. Performing χ2 test to compare
success  rates  of  the  two  different  harvesting  techniques
showed  a  significantly  higher  success  rate  with  forceps
stripping over hydrodissection (p≤0.05; Figure 1). Age of the
donors used for hydrodissection was 55±16 (mean±SD), and
age of donors used for stripping was 52±17 years (p>0.05).
Corneas  stained  with  0.4%  trypan  blue  for  1  min  before
removing  the  Descemet  membrane  showed  complete
endothelial  cell  death  several  days  after  harvesting.  In
successfully  cultured  cells,  the  ability  to  proliferate  was
maintained for several months. Before reaching confluence,
cells  had  an  uneven,  sometimes  stretched  shape,  which
resembled to some extent a fibroblastic appearance. After
reaching  confluence,  cells  exhibited  a  rounder,  polygonal
shape more similar to the morphology of endothelial cells in
vivo  (Figure  2).  This  appearance  was  especially  obvious
before the first passage. Cryopreservation of cells did not lead
to morphologic changes, and cells retained a similar speed of
growth for several weeks after thawing.
Stromal fibroblasts started growing out of corneal buttons
after approximately one week in culture. They exhibited a
typical,  spindle-shaped  appearance,  initially  reached
confluence within one additional week in culture (Figure 3),
and showed clear distinction from cultured HCECs.
Reverse  transcriptase  polymerase  chain  reaction  and
sequencing of COL8A2 cDNA: A 106 base pair (bp) RT–PCR
product of the size expected for COL8A2 was obtained with
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632cultured HCECs (Figure 4, lane 2). Pretreatment with DNase
did not diminish the strength of the obtained band (Figure 4,
lane 3). Sequence analysis of the obtained RT–PCR product
showed  100%  homology  to  the  human  COL8A2  cDNA
sequence  (UCSC  Genome  Bioinformatics).  RT–PCR  of
HCEC  total  RNA  with  commercially  available  β-actin
primers yielded a band of the expected 661 bp size (Figure 4,
lane 4). Human mononuclear cell total RNA was negative for
COL8A2 and positive for β-actin on RT–PCR analysis (Figure
4, lanes 5 and 6).
Transfection:
Lipid-/Liposome-mediated reagents—Transfection of
pIRES-EGFP  plasmid  with  Fugene  and  lipofectin  each
showed  a  rate  of  transfection  of  approximately  5%.  For
Figure 2. Human corneal endothelial cells after 10 days of culturing
before first passage. Cells exhibited a polygonal shape similar as in
vivo.
Figure 3. Human corneal stromal fibroblast cells after two weeks in
culture before first passage. Cells exhibited a characteristic spindle-
shaped appearance.
Fugene, optimal results were obtained with an incubation time
of 60 min, 1 µg DNA, and 6 µl Fugene. With lipofectin, the
most  successful  parameters  were  2  µg  DNA  and  20  µl
lipofectin with an incubation time of 6 h. The addition of
PlusReagent to lipofectin did not significantly alter the rate of
transfection.  The  rate  of  transfection  with  Fugene  and
lipofectin (with and without PlusReagent) was too small to
yield  a  positive  selection  by  the  addition  of  neomycin.
Different parameters led to a lower success of transfection.
Transfection  of  pEGFP-N1  with  GenCarrier2  showed  the
highest rate of transfection of all tested chemical reagents and
was approximately 20%. For GeneCarrier2, the optimal rate
of  transfection  was  obtained  with  3  µg  DNA  and  18  µg
GenCarrier2  with  an  incubation  time  of  45  min  (cell
suspension). Cell toxicity of the reagents was low (~5%) and
showed a concentration dependence.
Electroporation  and  cell-sorting—In  electroporation
experiments with the BTX method using pEGFP-N1 plasmid,
the highest yield was obtained with a setting of three electric
pulses and an interval of 100 ms, pulse length of 1 ms, and a
voltage of 150 V. Transfection rate with these parameters was
about  20%.  With  the  second  setting  tested  (as  described
above), success was considerably lower. Further evaluation
was not performed.
With the Amaxa nucleofector using pmaxGFP, the rate
of transfection varied from 20%–30% in the first two to four
Figure 4. RT-PCR of total RNA of HCECs and human mononuclear
cells for COL8A2 and β-actin. Agarose gel shows in lane 1: 1 kb plus
ladder, lane 2: COL8A2 with HCECs, lane 3: COL8A2 with HCECs,
pretreated with DNase (control to rule out DNA contamination), lane
4: β-actin (housekeeping gene serving as positive control), lane 5:
COL8A2 with human mononuclear cells (negative control), lane 6;
β-actin with human mononuclear cells (positive control), lane 7: no
template (negative control to rule out contamination of reagents),
lane 8: PCR with HiFi Taq of HCEC total RNA using COL8A2
primers (negative control to rule out contamination of HCEC total
RNA with genomic DNA).
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633Figure 5. Human corneal endothelial cells on day 5 after transfection with Amaxa. Fluorescence microscopy (A) shows a transfection rate of
~30% compared with corresponding bright-field image (B).
Figure 6. Human corneal endothelial cells transfected with Amaxa using pmaxGFP on day 3 after FACS. Fluorescence microscopy (A),
exhibits an essentially pure population of transfected cells as compared with corresponding bright-field image (B).
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days after transfection, depending on the electrical program
used as assessed by fluorescence microscopy. By day 5, rate
of transfection was 30% for all of the five electrical settings,
M-03, T-05, T-23, T-27, and U-11 (Figure 5). Electroporation
with Amaxa was performed once for each program. Four
additional replicates were performed using programs T-23
and  T-27  only  (see  Methods).  Variation  in  transfection
efficiency was dependent on the cell count used for each
electroporation procedure. Final cell count used for Amaxa
ranged between 4×105 and 6×105 per reaction.
BTX- and Amaxa-related cell death was approximately
10%. In cells transfected with the pEGFP-N1 plasmid (with
neomycin resistance gene), we added neomycin after five days
(as  fluorescence  increased  after  transfection  for
approximately  five  days).  After  10  days,  neomycin  was
removed from the medium. Removal of neomycin did not lead
to sufficient recovery of the cells. Selection with FACS after
electroporation with Amaxa was performed four times and led
to  a  nearly  homogeneous  population  of  transfected  cells
(Figure  6).  Gate  settings  were  chosen  to  select  a  pure
population of GFP-positive cells. These settings yielded a
percentage of 22%±14% (mean±SD) GFP-positive cells.
DISCUSSION
In this work, methods of harvesting, genetically modifying,
and enriching populations of HCECs were directly compared.
Our  main  focus  was  to  report  optimal  methods  that  are
technically  feasible  and  most  efficient  for  research  and
potentially clinical uses. The challenges of establishing and
maintaining  primary  HCEC  cultures  make  such  optimalFor harvesting HCECs, two different techniques were
assessed. The separation of DM by hydrodissection yielded
fewer  viable  cells  than  stripping  with  forceps.  It  seems
plausible that the stretching of DM while the bleb is forming
could damage the endothelial cells. In regard to clinical uses,
especially in the context of Descemet membrane endothelial
keratoplasty  (DMEK),  this  observation  could  be  of  great
importance [10] as hydrodissection as used in this study is also
a convenient and reliable way of harvesting donor DM for
possible use in DMEK (11). Further studies will be necessary
to assess the risks of damaging HCECs by hydrodissection of
DM before using this technique for clinical applications.
Previous  studies  of  HCEC  genetic  modification  have
primarily  focused  on  viral  methods  including  adenovirus,
adeno-associated virus, herpes simplex virus (HSV), human
immunodeficiency  virus  (HIV),  equine  infectious  anemia
virus (EIAV), and prototypic foamy virus (PFV) [5,12-14]
(Table  2).  Viral  transfection  bears  potential  risks  of
inappropriate viral replication or induction of host immune
responses  [15].  Furthermore,  use  of  retroviruses  requires
special safety precautions and bears the theoretical risk of
insertional mutagenesis. Thus, non-viral techniques could be
a safer and more practical approach. However, a drawback of
non-viral  techniques  is  generally  lower  transfection
efficiencies  and  lower  transgene  expression.  Additionally,
because  no  integration  in  the  host  genome  occurs,  gene
expression is typically transient. Further selection by use of
resistance markers could be used to obtain stably expressing
cells that have incorporated the transgene in their genome
[16,17].
In  previously  published  studies,  transfection  with
chemical reagents varied highly in efficiency depending on
the reagents used [18,19] (Table 2). The most successful rate
of transfection was obtained with lipofectin and was 17% as
reported by Dannowski et al. [18]. Our transfection rates were
lower using this reagent. The difference in the outcome might
be due to our assessing the transfection rate by fluorescence
microscopy and using a plasmid with a relatively low GFP
expression  level  (pIRES-EGFP).  Using  GenCarrier2  with
pEGFP-N1, our transfection rates were in the same range
(approximately 20%) as in other studies using lipid-based
reagents.  Selection  by  antibiotics  did  not  prove  to  be
successful due to the relatively low rates of transfection in the
liposome-/lipid-mediated  transfection  methods.  One
explanation for this may be that the transfection reagents
increased the sensitivity of the cells to the antibiotic. This is
unlikely as the antibiotic was added 48 h post-transfection,
and the cells did not appear to have undue toxicity at this time
point post-transfection.
Previous  publications  on  electroporation  methods
reported  a  lower  efficiency  than  in  our  work  [20,21].
However, the previously described methods used different
electroporation techniques. With both BTX and Amaxa, we
received a higher efficiency than with the chemical reagents
tested in this study. Our results also showed that toxicity was
present but lower than 20% as has been reported in several
previous studies on electroporation [19-21]· In our study, the
rate of transfection using electroporation is efficient enough
to select the transfected cells by flow cytometry to a nearly
pure population.
TABLE 2. PREVIOUS STUDIES OF HUMAN CORNEAL ENDOTHELIAL CELL GENETIC MODIFICATION.
Method Rate of transfection Reference
Viral vectors
adeno-associated virus, HSV 2%–5% [12]
EIAV 30% [5]
EIAV, adenovirus, HIV, PFV 43%–99% [13]







peptides (polyamidoamine) 2% [19]
Electroporation
GenePulser (BioRad) area of clonal proliferation [20]
Easyject Plus system (Eurogentec) 2.4% [21]
GenePulser (BioRad) large number of clones [22]
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methods  highly  relevant.  Furthermore,  HCEC  lines  are
limited  reagents,  which  make  extensive  analyses  more
difficult than for immortalized cell lines.Homogeneous, genetically modified HCECs could serve
as a promising therapeutic tool. These modifications could
include approaches to alter HCEC immunogenicity to prevent
allograft  rejection  or  enhance  proliferative  capacities  to
prevent cell loss after endothelial keratoplasty [23,24]. Some
concern  remains  that  the  fibroblastic  appearance  after
prolonged  culturing  could  be  due  to  de-differentiation.
However, prior studies assessed that physiologic functions of
cultured HCEC (such as the pump function of Na-K-ATPase
or zonula occludens-1 expression) resemble those in vivo [9,
25]. In addition, relatively early passages of cells could be
used  to  minimize  the  effects  of  possible  morphologic  or
functional changes before therapeutic use.
Early reports have described efforts to grow HCECs on
artificial  matrices  and  transfer  these  grafts  as  sheets  into
animal eyes or onto human donor corneas [25-27]. Another
potentially useful approach could involve seeding genetically
modified HCECs without a supporting material directly onto
in vivo corneal stroma denuded of pathologic endothelium
and/or DM [7,28,29]. Techniques to genetically modify and
select HCECs as shown in this study could lead to improved
success of future endothelial transplant procedures.
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